Devine S. Frundi

Physical performance and glycemic control under SGLT-2-inhibitors in patients with type 2 diabetes and established atherosclerotic cardiovascular diseases or high cardiovascular risk (PUSH): Design of a 4-week prospective observational study

M. Wilhelm, T. Muka, A. Bano, 2022, Frontiers in Cardiovascular Medicine.

Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement

F. Neumann, D. Trenk, W. Hochholzer, 2007, Thrombosis and Haemostasis.

Whole blood aggregometry for evaluation of the antiplatelet effects of clopidogrel.

F. Neumann, D. Trenk, W. Hochholzer, 2007, Thrombosis research.

Time Dependence of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention

F. Neumann, D. Trenk, W. Hochholzer, 2005, Circulation.